Table 3.
Multivariable models of crude and adjusted HR (95% CIs) for breast cancer recurrence, distant metastasis, and overall survival for the entire follow-up and 5-year follow-up in relation to pSTAT3Y705 level.
BREAST CANCER RECURRENCE | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | ||||||||||||||||
Total | Events | Crude | Adjusted | Adjusted | Adjusted | |||||||||||||
Tumor pSTAT3Y705 status | n | n | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | ||||
Negative | 210 | 40 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 95 | 0.89 | 0.61 | 1.28 | 0.53 | 0.91 | 0.63 | 1.32 | 0.62 | 1.13 | 0.76 | 1.67 | 0.54 | 1.13 | 0.76 | 1.68 | 0.54 |
High | 51 | 2 | 0.24 | 0.06 | 1.00 | 0.051 | 0.26 | 0.06 | 1.07 | 0.061 | 0.41 | 0.10 | 1.74 | 0.23 | 0.39 | 0.09 | 1.62 | 0.19 |
Ptrend | 0.10 | 0.14 | 0.89 | 0.84 | ||||||||||||||
Tumor pSTAT3Y705 status | n | n | HR 5-year | HR 5-year | HR 5-year | HR 5-year | ||||||||||||
Negative | 210 | 27 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 47 | 0.58 | 0.36 | 0.94 | 0.026 | 0.64 | 0.40 | 1.02 | 0.063 | 0.82 | 0.50 | 1.35 | 0.43 | 0.80 | 0.48 | 1.32 | 0.38 |
High | 51 | 1 | 0.14 | 0.02 | 1.07 | 0.058 | 0.17 | 0.02 | 1.25 | 0.082 | 0.29 | 0.04 | 2.18 | 0.23 | 0.28 | 0.04 | 2.07 | 0.21 |
Ptrend | 0.004 | 0.014 | 0.22 | 0.18 | ||||||||||||||
DISTANT METASTASIS | ||||||||||||||||||
Model 1 | Model 2 | Model 3 | ||||||||||||||||
Total | Events | Crude | Adjusted | Adjusted | Adjusted | |||||||||||||
Tumor pSTAT3Y705 status | n | n | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | ||||
Negative | 210 | 30 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 56 | 0.70 | 0.45 | 1.10 | 0.12 | 0.71 | 0.46 | 1.12 | 0.14 | 0.96 | 0.60 | 1.53 | 0.86 | 0.95 | 0.60 | 1.53 | 0.84 |
High | 51 | 2 | 0.33 | 0.08 | 1.39 | 0.13 | 0.35 | 0.08 | 1.46 | 0.15 | 0.65 | 0.15 | 2.77 | 0.56 | 0.63 | 0.15 | 2.69 | 0.53 |
Ptrend | 0.046 | 0.058 | 0.68 | 0.65 | ||||||||||||||
Tumor pSTAT3Y705 status | n | n | HR 5-year | HR 5-year | HR 5-year | HR 5-year | ||||||||||||
Negative | 210 | 21 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 28 | 0.45 | 0.26 | 0.79 | 0.006 | 0.48 | 0.27 | 0.85 | 0.011 | 0.66 | 0.36 | 1.19 | 0.17 | 0.64 | 0.35 | 1.17 | 0.15 |
High | 51 | 0 | No event | No event | No event | No event | ||||||||||||
Ptrend | 0.0008 | 0.0018 | 0.060 | 0.051 | ||||||||||||||
DEATH | ||||||||||||||||||
Model 1 | Model 2 | Model 3 | ||||||||||||||||
Total | Events | Crude | Adjusted | Adjusted | Adjusted | |||||||||||||
Tumor pSTAT3Y705 status | n | n | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | HR | (95% CI) | P-value | ||||
Negative | 210 | 36 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 72 | 0.78 | 0.52 | 1.17 | 0.23 | 0.79 | 0.52 | 1.18 | 0.25 | 0.98 | 0.63 | 1.50 | 0.91 | 0.96 | 0.62 | 1.48 | 0.86 |
High | 51 | 5 | 0.74 | 0.29 | 1.90 | 0.53 | 0.76 | 0.29 | 1.94 | 0.56 | 1.20 | 0.46 | 3.14 | 0.71 | 1.19 | 0.45 | 3.10 | 0.73 |
Ptrend | 0.25 | 0.27 | 0.91 | 0.96 | ||||||||||||||
Tumor pSTAT3Y705 status | n | n | HR 5-year | HR 5-year | HR 5-year | HR 5-year | ||||||||||||
Negative | 210 | 25 | Ref | Ref | Ref | Ref | ||||||||||||
Intermediate | 606 | 39 | 0.54 | 0.33 | 0.90 | 0.018 | 0.56 | 0.34 | 0.93 | 0.024 | 0.68 | 0.40 | 1.16 | 0.15 | 0.65 | 0.38 | 1.11 | 0.11 |
High | 51 | 1 | 0.17 | 0.02 | 1.24 | 0.080 | 0.18 | 0.02 | 1.31 | 0.089 | 0.29 | 0.04 | 2.14 | 0.22 | 0.28 | 0.04 | 2.11 | 0.22 |
Ptrend | 0.004 | 0.007 | 0.078 | 0.058 |
Model 1: Time between surgery and staining.
Model 2: Adjusted for model 1 + age ≥50 years, tumor size, node status, grade III, ER status, HER2 status, and BMI ≥25 kg/m2. Missing data for 53 patients for at least one variable.
Model 3: Adjusted for model 1 + 2 + adjuvant treatments. Missing data for 55 patients for at least one variable.